Andrew Elnatan - Sellas Life Chemistry, Affairs

SLS Stock  USD 0.87  0.01  1.16%   

Executive

Andrew Elnatan is Chemistry, Affairs of Sellas Life Sciences
Address Times Square Tower, New York, NY, United States, 10036
Phone646 200 5278
Webhttps://www.sellaslifesciences.com

Sellas Life Management Efficiency

The company has Return on Asset of (1.2915) % which means that on every $100 spent on assets, it lost $1.2915. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (8.8806) %, meaning that it generated no profit with money invested by stockholders. Sellas Life's management efficiency ratios could be used to measure how well Sellas Life manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Sellas Life's Return On Capital Employed is comparatively stable compared to the past year. Return On Equity is likely to gain to 4.92 in 2024, whereas Return On Tangible Assets are likely to drop (9.11) in 2024. At this time, Sellas Life's Intangibles To Total Assets are comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.07 in 2024, whereas Total Assets are likely to drop slightly above 5.9 M in 2024.
Sellas Life Sciences has 906 K in debt with debt to equity (D/E) ratio of 0.06, which may show that the company is not taking advantage of profits from borrowing. Sellas Life Sciences has a current ratio of 2.31, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Sellas to invest in growth at high rates of return.

Similar Executives

Showing other executives

EXECUTIVE Age

Carter KingProtagonist Therapeutics
53
Michele PMPIovance Biotherapeutics
N/A
MBA MBAIovance Biotherapeutics
67
Sharon KlahreSyndax Pharmaceuticals
N/A
Gayle GirondaInozyme Pharma
N/A
Soojin KimInozyme Pharma
N/A
Carena SpiveyProtagonist Therapeutics
N/A
Sara PellegrinoIovance Biotherapeutics
N/A
PharmD RasbachZentalis Pharmaceuticals Llc
44
Hequn YinIovance Biotherapeutics
59
Steve SabusSyndax Pharmaceuticals
57
FACP MDProtagonist Therapeutics
65
Matthew GoslingProtagonist Therapeutics
53
Andrea JDZentalis Pharmaceuticals Llc
43
Asif AliProtagonist Therapeutics
50
Richard ShamesProtagonist Therapeutics
64
Mohammad MasjedizadehProtagonist Therapeutics
N/A
Ingmar MDZentalis Pharmaceuticals Llc
49
Matthew JDProtagonist Therapeutics
53
Bo ChaoPuma Biotechnology
N/A
Kimberly FreemanZentalis Pharmaceuticals Llc
N/A
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company was founded in 2012 and is headquartered in New York, New York. Sellas Life operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people. Sellas Life Sciences (SLS) is traded on NASDAQ Exchange in USA. It is located in Times Square Tower, New York, NY, United States, 10036 and employs 16 people. Sellas Life is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Sellas Life Sciences Leadership Team

Elected by the shareholders, the Sellas Life's board of directors comprises two types of representatives: Sellas Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sellas. The board's role is to monitor Sellas Life's management team and ensure that shareholders' interests are well served. Sellas Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sellas Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Esq, General VP
Jrg Breitkopf, Head Operations
ScD MD, President, Founder
Barbara Wood, Gen VP
Andrew Elnatan, Chemistry, Affairs
Robert Francomano, Senior Officer
Stacy Yeung, Associate VP
MBA MD, Senior Development
John CPA, Sr Officer

Sellas Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sellas Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sellas Stock Analysis

When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.